Exon 20 Group, a multistakeholder organization
@Exon20Group
Followers
2K
Following
2K
Media
10
Statuses
1K
Global org: patients/carers, HCPs, pharma, labs, scientists, working to cure #NSCLC #HER2 & #EGFR #Exon20 insertions (in 25 cancers +) [email protected]
83 countries served
Joined July 2017
@JennyCarlisleMD @TumorBoardTues @LealTiciana @FordePatrick @DrMarkAwad @JulieBrahmer @TonyMok9 @RamalingamMD @RachelSanbornMD @KarenReckampMD @AnaVManana @DevikaDasMD @JSabari @CharuAggarwalMD @tehfem @ElizSMcKenna @JineshGheeya @ShrutiPatelMD @NarjustFlorezMD @HosseinBorghaei @ThanksCancer @IASLC @IbiayiMD @NCCN @JohnEbbenMDPhD @oncoOuLungCA @drkpavithran @DrSteveMartin @khushmanmd @RenoHemonc @VivekSubbiah @StephenVLiu @juanosoriomd @n8pennell @LeciaSequist @NicoleKuderer @bensolomon1 @DavidOReilly2 @US_FDA @Latinamd @ShaalanBeg @msalmanfaisal @ADesaiMD @_Vila_L @FawziAbuRous @DrZ_84 @idamicaily @ASCO Don’t let your #EGFR #Exon20 and #HER2 #Exon20 patients miss out on the wonderful, caring community of patients and care partners (+ family members) in the multi-stakeholder @Exon20Group We have peer-to-peer counseling through our Angel Buddies program, oncology nursing services,.
0
3
22
RT @Larvol: Top 10 #LungCancer Oncologists for June 2025, curated by @Larvol CLIN. Explore more about oncology conferences, top trials, an….
0
13
0
RT @IASLC: How should clinicians approach resectable EGFR-mutant #NSCLC? On the latest #LungCancerConsidered episode, @StephenVLiu moderate….
0
9
0
RT @Latinamd: More great news for patients with rare mutations: @FDAOncology approved today #Sunvozertinib (Zegfrovy) oral TKI for #EGFR20….
0
2
0
RT @StephenVLiu: FDA grants accelerated approval to sunvozertinib (200mg po qd) for EGFR exon 20 insertion NSCLC after chemotherapy. In WU-….
0
14
0
RT @lungoncdoc: New @US_FDA accelerated approval: Sunvozertinib for EGFR exon20ins NSCLC after platinum chemo. ▫️n=85, WU-KONG1B.▫️ORR: 46%….
0
12
0
Delighted to see the FDA approval of #sunvozertinib, #Dizal Pharma's TKI, for #EGFR #Exon20 patients! Congratulations to the patients, care partners, investigators and #WuKong study teams!.
0
2
14
Another brilliant talk from #DavaLung Co-Chair @Jsabari whose expertise @nyulangone in both EGFR and HER2 exon 20 has continued to assist countless patients and their family members. A role model for everyone else! COCOON has been the standard of care since ELCC 2025 and.
Dr. @Jsabari (@nyulangone) presents a deep dive on amivantamab + lazertinib in EGFRm NSCLC at #DAVALung, highlighting efficacy from MARIPOSA and the importance of proactive dermatologic care to manage its unique AE profile.
0
1
6
RT @Latinamd: #HawaiiLung25 @christinemphmd @WeillCornell presents on the possibilities of incorporating large real world data, NLP to impr….
0
4
0
RT @DAVAOnc: Dr. Heather Wakelee (@HwakeleeMD) discussed evolving outcomes with ICIs in NSCLC. IMpower010 shows DFS benefit in KRAS G12C, B….
0
2
0
Sunvozertinib is missing!.
✅ FDA Accelerated Approval Alert – June 23, 2025. The FDA has granted accelerated approval to Datroway (datopotamab deruxtecan-dlnk, Daiichi Sankyo) for adults with EGFR-mutated advanced NSCLC who’ve previously received EGFR therapy and platinum chemo. Approval is based on data
2
0
3
Zongertinib has the mildest side effects of any drug—ever—in the Exon 20 Group, and our HER2 Warriors cannot praise it enough. So grateful to John Heymach for being international PI of the practice-changing zongertinib study. #DAVALung.
0
4
12
Great #DAVALung talk on MARIPOSA. And with @jillfeldman4 compelling presentation at ASCO 2025 on tox-mitigating strategies in the COCOON trial for amivantamab/lazertinib, MARIPOSA is a very sound option for life extension. Med oncs who are not familiar with ami/laz: Please.
Dr. @Jsabari (@nyulangone) presents a deep dive on amivantamab + lazertinib in EGFRm NSCLC at #DAVALung, highlighting efficacy from MARIPOSA and the importance of proactive dermatologic care to manage its unique AE profile.
1
4
16
Excellent presentation from @chulkimMD on NVL-330 and HEROEX-1–more clinical trial sites needed in the U.S. and abroad. #DAVALung.
Promising developments in #lungcancer! @chulkimMD of @Georgetown discusses NVL-330 for HER2-altered NSCLC, preclinical tumor regression up to 83%, intracranial activity vs. T-DXd, and early clinical insights from the ongoing HEROEX-1 trial. #DAVALung #NSCLC
0
1
11
RT @StephenVLiu: FDA grants accelerated approval for datopotamab deruxtecan, anti-TROP2 ADC, for #EGFR mutant NSCLC after prior TKI and che….
0
33
0
Great to have Bob Hanlon, our Exon 20 Group co-founder and chair, and Steve Potts, ICAN’s chair of Drug Development, on the same panel discussing a huge issue that will jeopardize small molecule drug development if not fixed. Find out more by following Duane’s Vital.
Just because IRA is a serious problem, doesn’t mean we can’t have fun discussing it. Big thanks to Steve Potts @DesertBiopharma for the panel invitation with @G17Esiason, @BarbaraMcAneny, @Rfonsi1, and Robert Hanlon of @Exon20Group
0
0
1
RT @SmartBiology3D: Biology is always advancing—and so are we. We use scientifically accurate 3D visualizations to bring the most current….
0
165
0
RT @mirrorsmed: Outcomes with trastuzumab deruxtecan by biomarker status, line of treatment and prior receipt of sacituzumab govitecan in a….
0
10
0
Superb and highly energized podcast hosted by Duane Schulthess, Managing Director, @VitalTransform Every pharma, biotech, advocacy organization, Member of Congress, and frankly every citizen who cares about drug development and healthcare needs to tune in! Proud of Duane and the.
In an ever-evolving healthcare landscape, understanding how policy shapes innovation becomes increasingly important. Without that understanding - barriers to drug development, such as uneven exclusivity periods, can halt the development of new treatments. We sat down for a
0
0
1